title: The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer.
abstract: Objective:To evaluate the effect of bevacizumab in different lines for Chinese patients with metastatic colorectal cancer (mCRC).Methods:Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2007 to 2013 were recruited as study and control group. Endpoints were overall survival (OS), progression free survival (PFS), objective response rate (ORR) and disease control rate (DCR). Corresponding survival rates of first- and second-line in study and control group were compared.Results:1. Median OS of study and control group were 44.8 (95% CI: 37.1~52.4) months, 36.1 (95% CI: 32.8~39.5) months respectively, which were significantly different (P=0.004). 2. In the first line treatment, median OS of study and control group were 49.9(95% CI: 40.1~59.8) months and 36.1 (95% CI: 32.7~39.4) months (P=0.002), respectively. And median PFS were 10.1(95% CI: 8.7~11.5) months and 6.2 (95% CI: 5.5~6.8) months (P<0.001), respectively. 3. In the second line treatment, median OS of study and control group were 34.8 (95% CI: 26.3~43.3) months and 24.6 (95% CI: 22.2~27.0) months (P=0.022), respectively. And the mPFS were 6.3 (95% CI: 4.7~7.8) months and 3.1 (95% CI: 2.5~3.6) months (P<0.001), respectively. 4. Median OS of first- and second-line treatment of the study groups were 49.9(95% CI: 40.1~59.8) months and 34.8 (95% CI: 26.3~43.3) months (P=0.189), respectively.Conclusion:The combination of bevacizumab and chemotherapy had a promising efficacy in Chinese mCRC patients. However, their OS were statistically insignificant between first- and second-line of bevacizumab groups.
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; ICU, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Chenxi
authors.initials: C
authors.lastname: Yin
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; ICU, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Gang
authors.initials: G
authors.lastname: Ma
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Yuming
authors.initials: Y
authors.lastname: Rong
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Pengfei
authors.initials: P
authors.lastname: Kong
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Yang
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Chang
authors.initials: C
authors.lastname: Jiang
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Fangxin
authors.initials: F
authors.lastname: Liao
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Wenzhuo
authors.initials: W
authors.lastname: He
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China;; VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China.
authors.forename: Liangping
authors.initials: L
authors.lastname: Xia
keywords: bevacizumab; chemotherapy line setting; efficacy.; mCRC